UCB Pharma (United Kingdom)

Recent papers from UCB Pharma (United Kingdom)

1. Concepts and Assessment of Fatigue in Myasthenia Gravis: A Scoping ReviewNeurology and Therapy · 2026
2. Bimekizumab in Chinese Patients with Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results from the Phase 3 BE MOBILE 1 StudyRheumatology and Therapy · 2026
3. HiSQOL-mini: Development and Validation of a Shortened Version of the Hidradenitis Suppurativa Quality of Life (HiSQOL) InstrumentBritish Journal of Dermatology · 2026
4. Distilling Direct Effects via Conditional Differential Gene Expression AnalysisBioinformatics · 2026
5. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trialThe Lancet · 2021
6. Surface charge alterations in urinary extracellular vesicles mirror diabetic kidney disease pathophysiologyFEBS Journal · 2026
7. Bimekizumab efficacy across GRAPPA domains to 3 years in patients with psoriatic arthritis: a post hoc analysis of two phase 3 studiesLara D. Veeken · 2026
8. Epigenetic modulation of stromal cell states underpins pathological tissue niches in Crohn’s diseaseNature Immunology · 2026
9. Bimekizumab Clinical Efficacy Up to 2 Years Across Patients with Psoriatic Arthritis and Varying Baseline Joint Involvement: Results from a Post Hoc Analysis of 2 Pooled Phase 3 StudiesThe Journal of Rheumatology · 2026
10. Bimekizumab Demonstrated Comparable 1-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from 2 Phase 3 StudiesThe Journal of Rheumatology · 2026
11. Bimekizumab Demonstrated Early and Sustained Efficacy Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis: Pooled Post Hoc Results Up to 1-Year from Two Phase 3 StudiesThe Journal of Rheumatology · 2026
12. Long-Term Uveitis Rates with Bimekizumab Treatment Across Pooled Phase 2B and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year UpdateThe Journal of Rheumatology · 2026
13. Characterising skull pathologies in the Sost -deficient mouse for preclinical evaluation of sclerosteosis treatmentsDisease Models & Mechanisms · 2026
14. Recommendations for the use of clinical outcome assessments in rare disease drug developmentEClinicalMedicine · 2026
15. Sp1 links CD46 to CD4 T cell metabolic fitness, survival, and retroviral controlScience Immunology · 2026
16. Bimekizumab Improves Health Status and Work Productivity, With Reduced Productivity Costs, to 3 Years in Axial Spondyloarthritis and Psoriatic ArthritisThe Journal of Rheumatology · 2026
17. Molecular basis for depsipeptide HDAC inhibitor combinatorial biosynthesisNature Communications · 2026
18. The uptake, intracellular trafficking and recycling of FcRn-blocking therapeutics in human endothelial cells in vitroCellular Immunology · 2026
19. Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results from Two Phase 3 StudiesThe Journal of Rheumatology · 2026
20. Disease burden of untreated thymidine kinase 2 deficiency: insights from a large patient datasetBrain Communications · 2026